Merck makes first entry in Japanese OTC market with Bion 3
Merck KGaA has placed its probiotics, multivitamin and mineral combination product on the Japanese market, the world's second-largest for over- the-counter health remedies.
Merck KGaA has placed its probiotics, multivitamin and mineral combination product on the Japanese market, the world's second-largest for over- the-counter health remedies.
Merck Selbstmedikation GmbH, a subsidiary of Merck Consumer Health Care (CHC), has granted exclusive licensing and marketing rights in the Japanese market to SATO Pharmaceutical Co for Bion 3. The agreement covers the manufacturing, packaging, marketing, use and selling of Bion 3 in Japan by SATO Pharmaceutical.
"We believe that Bion 3, the first product to uniquely combine probiotics with multivitamins and minerals, will be well received in Japan, where consumers are discerning and health conscious," said Peter Shotter, head of Merck's Consumer Health Care division.